Evidence map›Paper›PMID 42840575›Full record

ReviewFrontiers in immunology2026

Beyond Foxp3 and TSDR: a dual epigenetic lock framework for treg stability and plasticity.

Feng Wang, Haiying Yang, Zhiguo Xu, Jingxian Song, Zijun Wang, Le Wang

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Feng WangHuzhou Central Blood Station, Huzhou, China.
Haiying YangHuzhou Central Blood Station, Huzhou, China.
Zhiguo XuHuzhou College of Life and Health, Huzhou, China.
Jingxian SongHuzhou Central Blood Station, Huzhou, China.
Zijun WangZhejiang Chinese Medical University, Hangzhou, China.
Le WangHuzhou Central Blood Station, Huzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Regulatory T cells (Tregs) maintain immune homeostasis by balancing lineage stability with functional adaptability. Although Foxp3 is central to Treg identity, Foxp3 expression alone does not fully explain the long-term maintenance of suppressive function or the capacity of Tregs to adapt to diverse tissue environments. Similarly, Foxp3 TSDR demethylation provides a durable epigenetic imprint but does not account for the dynamic regulation of broader Treg functional programs. Here, we propose the Dual Epigenetic Lock framework as a conceptual and testable model in which two complementary epigenetic layers contribute to Treg state regulation. The first lock consists of stable TSDR demethylation, which preserves lineage-associated Foxp3 expression competence. The second lock is proposed to involve Treg-associated super-enhancer networks that may stabilize suppressive transcriptional programs, regulate environmental adaptation, and constrain inappropriate inflammatory activation. This framework suggests that Treg stability emerges from the integration of durable lineage memory and dynamic functional regulation rather than from a single molecular determinant. Disruption of this balance may contribute to impaired immune tolerance in autoimmune diseases, whereas excessive reinforcement of suppressive regulatory programs may support tumor immune evasion. However, the extent to which these two epigenetic layers are mechanistically coupled remains unresolved. Emerging approaches including single-cell multi-omics, spatial epigenomics, and targeted epigenome engineering provide opportunities to test whether the dual-lock architecture predicts Treg state transitions and therapeutic responsiveness. This framework also provides a conceptual basis for two complementary therapeutic strategies: reinforcing Treg stability for immune tolerance and selectively modulating tumor-associated Treg programs for cancer immunotherapy.

Indexed as

Cell PlasticityEpigenesis, GeneticForkhead Transcription FactorsT-Lymphocytes, RegulatoryAnimalsDNA MethylationHumansImmune ToleranceSuper EnhancersForkhead Transcription FactorsFOXP3 protein, humanCAR-Treg engineeringepigenetic plasticityex-Treg conversionregulatory T cells (Tregs)super-enhancersTET dioxygenasesTSDR demethylation

Identifiers

PMID42840575
PMCPMC13640018

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.